Evaluation of the United States Public Health Service Guidelines for Discontinuation of Anticytomegalovirus Therapy After Immune Recovery in Patients With Cytomegalovirus Retinitis

Discontinuation of anti-CMV therapy after immune recovery did not increase the risk of poor outcomes. These results support the current guidelines for discontinuation of anti-CMV therapy after achievement of sustained immune recovery.